跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 28,140 条关于
“HLB Group”
全部
28,140
临床试验
19,008
药物
1,008
机构
515
资讯
7,609
去年
HLB Group to Resubmit Riboceranib for FDA Approval Following Second Rejection
6个月前
Korean Biotech Companies to Showcase Next-Generation Cancer Therapies at AACR 2026
去年
Verismo Therapeutics Advances KIR-CAR Platform with HLB Innovation Merger and IFLI Partnership
去年
ESMO Endorses HLB's CAM-RIVO for First-Line Liver Cancer Treatment Ahead of FDA Decision
去年
FDA Issues Second Rejection for Rivoceranib/Camrelizumab Combination in Unresectable Liver Cancer
去年
FDA Rejects Hengrui-HLB Liver Cancer Combination Therapy for Second Time
2个月前
EPA Approves CRISPR-Based HLB-Resistant Citrus Rootstock to Combat Citrus Greening
去年
FDA Accepts Resubmission of NDA for Rivoceranib and Camrelizumab in Unresectable Hepatocellular Carcinoma
29天前
HLB Reports Sharp Revenue Decline and Widening Losses in H1 2025 Amid Oncology Pipeline Push
去年
HLB Advances Cancer Drug Pipeline: Rivoceranib FDA Decision Due March, Plans RLY-4008 Development
第 1 页,共 761 页
上一页
下一页